TGKQ.F · Precipio, Inc

-

Please sign in to comment on TGKQ.F

1 Comment

Admin

4 years ago

Precipio, Inc is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.

From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.

Precipio, Inc's total revenue rose by 182.1% to $2M since the same quarter in the previous year.

Its net income has increased by 50.6% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 31.0% to $-1M since the same quarter in the previous year.

Based on the above factors, Precipio, Inc gets an overall score of 5/5.

Exchange	F
CurrencyCode	EUR
ISIN	US74019L5030
Sector	Healthcare
Industry	Diagnostics & Research

Dividend Yield	0.0%
Market Cap	367K
PE Ratio	None
Beta	2.04
Target Price	7

ABOUT

Precipio, Inc

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.

TGKQ.F · Precipio, Inc

-

Precipio, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Precipio, Inc using a moving average strategy